Johnson & Johnson agrees $5.5bn talc settlement

Johnson & Johnson has struck a $5.5bn settlement covering roughly 76,000 US plaintiffs who claimed the company's talcum powder products caused ovarian cancer, according to the Financial Times. The deal closes one of the largest and longest-running product liability sagas in American corporate history, one that has dogged the healthcare and consumer group for years and repeatedly complicated its efforts to draw a line under the litigation through bankruptcy manoeuvres involving a subsidiary.

For a business with a significant consumer health and personal care footprint, the settlement removes a persistent overhang that has weighed on investor sentiment and management attention. J&J discontinued talc-based baby powder in North America some years ago and has since replaced it with cornstarch-based alternatives globally, but the legal exposure from historic sales continued to generate litigation risk long after the product itself left shelves.

The scale of the payout underscores the financial consequences that consumer-facing companies face when safety concerns attach to a legacy product, even one no longer sold. For luxury and prestige beauty brands that increasingly emphasise ingredient transparency and clean formulations, the case is a reminder that reputational and legal risk in personal care can outlast a product by decades, and that settling at scale, however costly, can be preferable to prolonged uncertainty.

Support the content you love — it’s free 🎉

Add Worthbury as a preferred source on Google. Our stories will be more likely to appear in Google’s Top Stories. It’s free and supports our team. Thank you!

Add as preferred source

You can remove us any time in Google’s source preferences.

This briefing is published daily using an AI-powered system crafted by Worthbury's team and finely tuned to meet our editorial standards. While we continuously test and review the output, mistakes can sometimes happen. Tell us if you spot one.